Sponsors (32)
The bill strengthens and speeds federal authority to target fentanyl-related substances—likely reducing availability and aiding enforcement—while imposing broader Schedule I coverage and accelerated rulemaking that may hinder legitimate research, raise compliance and enforcement costs, and increase risks of overbroad prosecutions.
Law-enforcement and federal prosecutors will have clearer statutory authority and stiffer penalties for fentanyl-related substances, making it easier to charge, prosecute, and deter trafficking.
General public and border communities may see reduced availability of new fentanyl analogs, which could lower overdose risk and improve public health outcomes if enforcement and interdiction are effective.
Scientists, researchers, and research institutions will face streamlined research procedures (faster start-up timelines, single institutional registrations across sites, continuation protections, and institutional agent authority), reducing administrative burdens for approved Schedule I research.
Scientists, clinicians, and patients seeking new therapies will face greater barriers because broadly defined Schedule I coverage could impede legitimate research and therapeutic development on fentanyl analogs.
Pharmaceutical manufacturers, hospitals, and small businesses may incur increased compliance costs and uncertainty because a broad structural definition could capture legitimate compounds and require new controls.
Taxpayers and the federal budget may face higher costs from increased prosecutions, more severe sentences, and greater demands on DOJ/CBP resources without new appropriations.
Based on analysis of 7 sections of legislative text.
Classifies chemically defined fentanyl-related substances as Schedule I, updates penalty and import/export references, and expedites DOJ/DEA rulemaking and research registration rules.
Creates a broad, class-wide Schedule I designation for any "fentanyl-related substance" defined by a set of structural chemical modifications and makes related changes to criminal penalties and import/export law. It also directs the Attorney General to issue expedited rules, allows interim final rules without the usual "good cause" finding, and requires the Drug Enforcement Administration and Department of Justice to adopt tailored research registration and operational rules for scientists working with Schedule I substances. The bill adds a statutory definition of “fentanyl-related substance,” inserts that definition into sentencing and import/export provisions, clarifies cross-references in prior law, and sets effective-date and procedural rules so the scheduling and penalty changes apply on enactment even if implementing regulations are not yet finalized. It includes transparency and reporting requirements for fentanyl research and a one-year OIG report to Congress on research with fentanyl-related substances.
Official title: Amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.
Introduced January 30, 2025 by Bill Cassidy · Last progress July 16, 2025